These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38493804)

  • 21. Comparison of 3'-deoxy-3'-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma.
    Jeong SY; Lim SM
    Nucl Med Biol; 2012 Oct; 39(7):977-81. PubMed ID: 22483845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
    Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.
    Pauleit D; Zimmermann A; Stoffels G; Bauer D; Risse J; Flüss MO; Hamacher K; Coenen HH; Langen KJ
    J Nucl Med; 2006 Feb; 47(2):256-61. PubMed ID: 16455631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer.
    von Forstner C; Egberts JH; Ammerpohl O; Niedzielska D; Buchert R; Mikecz P; Schumacher U; Peldschus K; Adam G; Pilarsky C; Grutzmann R; Kalthoff H; Henze E; Brenner W
    J Nucl Med; 2008 Aug; 49(8):1362-70. PubMed ID: 18632830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
    Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
    Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT.
    Zhao S; Kuge Y; Kohanawa M; Takahashi T; Zhao Y; Yi M; Kanegae K; Seki K; Tamaki N
    J Nucl Med; 2008 Jan; 49(1):135-41. PubMed ID: 18077525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
    Shah C; Miller TW; Wyatt SK; McKinley ET; Olivares MG; Sanchez V; Nolting DD; Buck JR; Zhao P; Ansari MS; Baldwin RM; Gore JC; Schiff R; Arteaga CL; Manning HC
    Clin Cancer Res; 2009 Jul; 15(14):4712-21. PubMed ID: 19584166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.
    Jensen MM; Erichsen KD; Björkling F; Madsen J; Jensen PB; Højgaard L; Sehested M; Kjær A
    PLoS One; 2010 Sep; 5(9):e12965. PubMed ID: 20885974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
    Yamane T; Takaoka A; Kita M; Imai Y; Senda M
    Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of new PET tracers for lung cancer.
    Szyszko TA; Yip C; Szlosarek P; Goh V; Cook GJ
    Lung Cancer; 2016 Apr; 94():7-14. PubMed ID: 26973200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors.
    Goggi JL; Bejot R; Moonshi SS; Bhakoo KK
    J Nucl Med; 2013 Sep; 54(9):1630-6. PubMed ID: 23907757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
    Giammarile F; Billotey C; Lombard-Bohas C; Le Bars D; Bournaud C; Masson S; Walter T; Houzard C; Scoazec JY; Hervieu V; Vuillez JP; Cornu C; Janier M; Borson-Chazot F
    Nucl Med Commun; 2011 Feb; 32(2):91-7. PubMed ID: 21076344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical evaluation of the anti-tumor effects of the natural isoflavone genistein in two xenograft mouse models monitored by [18F]FDG, [18F]FLT, and [64Cu]NODAGA-cetuximab small animal PET.
    Honndorf VS; Wiehr S; Rolle AM; Schmitt J; Kreft L; Quintanilla-Martinez L; Kohlhofer U; Reischl G; Maurer A; Boldt K; Schwarz M; Schmidt H; Pichler BJ
    Oncotarget; 2016 May; 7(19):28247-61. PubMed ID: 27070087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results.
    Pauleit D; Stoffels G; Schaden W; Hamacher K; Bauer D; Tellmann L; Herzog H; Bröer S; Coenen HH; Langen KJ
    J Nucl Med; 2005 Mar; 46(3):411-6. PubMed ID: 15750152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors.
    Choi SJ; Kim JS; Kim JH; Oh SJ; Lee JG; Kim CJ; Ra YS; Yeo JS; Ryu JS; Moon DH
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):653-9. PubMed ID: 15711980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of biological parameters in head and neck cancer based on in vivo distribution of
    Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W
    Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
    Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
    Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies.
    Mittra ES; Koglin N; Mosci C; Kumar M; Hoehne A; Keu KV; Iagaru AH; Mueller A; Berndt M; Bullich S; Friebe M; Schmitt-Willich H; Gekeler V; Fels LM; Bacher-Stier C; Moon DH; Chin FT; Stephens AW; Dinkelborg LM; Gambhir SS
    PLoS One; 2016; 11(2):e0148628. PubMed ID: 26890637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study.
    Blanchet EM; Taieb D; Millo C; Martucci V; Chen CC; Merino M; Herscovitch P; Pacak K
    J Nucl Med; 2015 Dec; 56(12):1849-54. PubMed ID: 26359261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.